Multiple Sclerosis Medical Cannabis UK

Medical Cannabis for MS: UK Context

• Multiple sclerosis is the most established indication for cannabis-based medicines in the UK.
• Sativex (nabiximols), a cannabinoid oromucosal spray, is licensed in the UK for MS-related spasticity.
• NICE recommends Sativex for MS spasticity when other spasticity treatments have not provided adequate relief.
• Broader cannabis products (oils, dried flower) are also prescribed privately for MS-related pain, sleep, and anxiety.

MS affects around 130,000 people in the UK, making it one of the most common serious neurological conditions. Cannabis-based medicines have the longest regulatory history of any cannabis medicine in the UK, with Sativex available through specialist prescription since 2010.

Sativex vs Broader Cannabis Products for MS in the UK

• Sativex is the only licensed cannabis medicine for MS spasticity and can be prescribed by NHS neurologists.
• Unlicensed cannabis products (dried flower, full-spectrum oils) are prescribed “off-label” for MS symptoms beyond spasticity.
• Private clinics can prescribe both Sativex and unlicensed products; NHS prescribing of unlicensed products is very rare.
• Patients with MS pain, sleep disturbance, bladder issues, and fatigue may benefit from broader cannabis medicines.

The distinction between licensed and unlicensed cannabis products is important for MS patients navigating the UK system. Sativex has the strongest regulatory backing, while other cannabis products may address a broader range of MS symptoms.

How MS Patients Access Medical Cannabis in the UK

• NHS neurologists can prescribe Sativex for eligible MS spasticity patients under NICE guidance.
• Private specialist clinics can prescribe both Sativex and other cannabis medicines for MS patients who do not qualify for NHS prescribing.
• Patients need a confirmed MS diagnosis and documentation of prior spasticity or symptom management failure.
• The MS Society UK maintains up-to-date guidance on cannabis access which patients are encouraged to consult.

MS patients in the UK have more NHS access to cannabis-based medicines than patients with most other conditions, thanks to the Sativex NICE approval. However, many MS patients still turn to private clinics for broader cannabis treatment of symptoms not covered by the NICE indication.

Costs for MS Patients

• Sativex via NHS: available at no cost to eligible MS patients under NICE guidance.
• Private Sativex prescription: approximately £350–£600 per month through private pharmacies.
• Unlicensed cannabis products via private clinic: £80–£250 per month depending on type and dose.
• Initial private specialist consultation for MS: £150–£280.

MS patients who qualify for NHS Sativex under NICE guidance should always explore this route first before turning to private prescribing. For those seeking broader cannabis treatment of MS symptoms, the private clinic route is the realistic option.